TARA

Protara Therapeutics Inc

Add to Watchlist

Advanced Chart

3.130

+0.03(0.968%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.210

Open

3.110

VWAP

3.13

Vol

265.83K

Mkt Cap

120.76M

Low

3.100

Amount

832.70K

EV/EBITDA(TTM)

Total Shares

20.59M

-4.76M

EV/OCF(TTM)

P/S(TTM)

Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.443

+2.91%

-0.410

-18%

-0.385

-14.44%

Estimates Revision

The market is revising No Change the revenue expectations for Protara Therapeutics, Inc. (TARA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -3.40%.

EPS Estimates for FY2025

Revise Downward

-4.64%

In Past 3 Month

Stock Price

Go Down

-3.40%

In Past 3 Month

4 Analyst Rating

523.00% Upside

Wall Street analysts forecast TARA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARA is 19.50 USD with a low forecast of 12.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

523.00% Upside

Current: 3.130

Low

12.00

Averages

19.50

High

23.00

523.00% Upside

Current: 3.130

Low

12.00

Averages

19.50

High

23.00

JonesResearch

Soumit Roy

Buy

initiated

$21

2025-05-22

Reason

JonesResearch

Soumit Roy

Price Target

$21

2025-05-22

initiated

Buy

Reason

JonesResearch analyst Soumit Roy initiated coverage of Protara Therapeutics with a Buy rating and $21 price target. The stock is currently trading at cash value, the analyst tells investors in a research note. The firm says Protara has three diverse, late-stage clinical programs, two of which are "fairly de-risked."

Scotiabank

George Farmer

Buy

Initiates

$12

2025-04-16

Reason

Scotiabank

George Farmer

Price Target

$12

2025-04-16

Initiates

Buy

Reason

Scotiabank analyst George Farmer initiated coverage of Protara Therapeutics with an Outperform rating and $12 price target. The company is developing a novel treatment for nonmuscle invasive bladder cancer, which the firm believes represents a "massive commercial opportunity," the analyst tells investors. As of now, no therapeutic approach stands out to us as a particular winner, which the firm thinks will be driving investor debate through 2027, but it believes the NMIBC market, which is "just beginning to be meaningfully tapped, could generate billions of dollars in sales over the next decade.

Cantor Fitzgerald

Li Watsek

Buy

Initiates

n/a

2025-03-14

Reason

Cantor Fitzgerald

Li Watsek

Price Target

n/a

2025-03-14

Initiates

Buy

Reason

Cantor Fitzgerald analyst Li Watsek initiated coverage of Protara Therapeutics with an Overweight rating.

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$23

2025-03-06

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$23

2025-03-06

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$23

2024-12-06

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$23

2024-12-06

Reiterates

Strong Buy

Reason

Guggenheim

Michael Schmidt

Strong Buy

Reiterates

$20

2024-12-06

Reason

Guggenheim

Michael Schmidt

Price Target

$20

2024-12-06

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Protara Therapeutics Inc (TARA.O) is -1.85, compared to its 5-year average forward P/E of -2.14. For a more detailed relative valuation and DCF analysis to assess Protara Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.14

Current PE

-1.85

Overvalued PE

0.03

Undervalued PE

-4.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.06

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.75

Undervalued EV/EBITDA

-0.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

6.59

Current PS

0.00

Overvalued PS

36.03

Undervalued PS

-22.84